Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10

1.

Differential regulation of a fibroblast growth factor-binding protein during skin carcinogenesis and wound healing.

Kurtz A, Aigner A, Cabal-Manzano RH, Butler RE, Hood DR, Sessions RB, Czubayko F, Wellstein A.

Neoplasia. 2004 Sep-Oct;6(5):595-602.

2.

Life cycle heterogeneity in animal models of human papillomavirus-associated disease.

Peh WL, Middleton K, Christensen N, Nicholls P, Egawa K, Sotlar K, Brandsma J, Percival A, Lewis J, Liu WJ, Doorbar J.

J Virol. 2002 Oct;76(20):10401-16.

3.

Detection of neutralizing antibodies against human papillomaviruses (HPV) by inhibition of gene transfer mediated by HPV pseudovirions.

Bousarghin L, Combita-Rojas AL, Touzé A, El Mehdaoui S, Sizaret PY, Bravo MM, Coursaget P.

J Clin Microbiol. 2002 Mar;40(3):926-32.

5.

The L1 major capsid protein of human papillomavirus type 16 variants affects yield of virus-like particles produced in an insect cell expression system.

Touze A, El Mehdaoui S, Sizaret PY, Mougin C, Muñoz N, Coursaget P.

J Clin Microbiol. 1998 Jul;36(7):2046-51.

6.

Isolation and propagation of human papillomavirus type 16 in human xenografts implanted in the severe combined immunodeficiency mouse.

Bonnez W, DaRin C, Borkhuis C, de Mesy Jensen K, Reichman RC, Rose RC.

J Virol. 1998 Jun;72(6):5256-61.

7.

In vitro infection and type-restricted antibody-mediated neutralization of authentic human papillomavirus type 16.

White WI, Wilson SD, Bonnez W, Rose RC, Koenig S, Suzich JA.

J Virol. 1998 Feb;72(2):959-64.

8.
9.
10.

Papilloma formation in human foreskin xenografts after inoculation of human papillomavirus type 16 DNA.

Brandsma JL, Brownstein DG, Xiao W, Longley BJ.

J Virol. 1995 Apr;69(4):2716-21.

Supplemental Content

Support Center